BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

2024-08-15-Proactive-CEO-interview-OTCQBPHIXF

August 16, 2024

OTC Market Center in New York welcomes PHI

Our very own ‘big apple’ news — PHI’s shares (OTCQB:PHIXF) are now also trading on the US-OTCQB Market! Go and see some snapshots and our CEO Patrik speaking on this exciting new chapter.

Interview-John-More-website

Interview with John Moore

Meet John Moore, the proposed new board member for PHI. John’s extensive experience and visionary mindset make him an invaluable addition to our team. Let’s dive into his journey and what made him interested in PHI.

Biostock-PHI-US-listing-interview

BioStock: PHI aims for US listing

BioStock has talked to PHI’s CEO, Patrik Eschricht, to learn more about what the dual listing on the US OTCQB market means for the company and its plans for the future.

biostock-phi-grows-its-network-of-collaborations-wheels-in-motion

BioStock: PHI grows its network of collaborations

BioStock caught up with PHI’s CEO Patrik Eschricht to ask about his outlook for the growing number of academic collaborations and sales partnerships.

12 3…7